150 related articles for article (PubMed ID: 3954780)
1. Antiprogestin-receptor complexes: differences in the interaction of the antiprogestin RU38,486 and the progestin R5020 with the progesterone receptor of human breast cancer cells.
Mullick A; Katzenellenbogen BS
Biochem Biophys Res Commun; 1986 Feb; 135(1):90-7. PubMed ID: 3954780
[TBL] [Abstract][Full Text] [Related]
2. Characterization of R5020 and RU486 binding to progesterone receptor from calf uterus.
Hurd C; Moudgil VK
Biochemistry; 1988 May; 27(10):3618-23. PubMed ID: 3408715
[TBL] [Abstract][Full Text] [Related]
3. Transformation of human progesterone receptor in the presence of the progestin (R5020) and the antiprogestin (RU486).
Miller MM; Hurd C; Moudgil VK
J Steroid Biochem; 1988 Nov; 31(5):777-83. PubMed ID: 3199817
[TBL] [Abstract][Full Text] [Related]
4. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
Horwitz KB
Endocrinology; 1985 Jun; 116(6):2236-45. PubMed ID: 4039656
[TBL] [Abstract][Full Text] [Related]
5. Ionic and ligand-specific effects on the DNA binding of progesterone receptor bound to the synthetic progestin R5020 and the antiprogestin RU486.
Chao CC; Thomas TJ; Ebede P; Gallo MA; Thomas T
Cancer Res; 1991 Aug; 51(15):3938-45. PubMed ID: 1855211
[TBL] [Abstract][Full Text] [Related]
6. Differences in the association of the progesterone receptor ligated by antiprogestin RU38486 or progestin ORG 2058 to chromatin components.
Geier A; Bella R; Beery R; Haimsohn M; Lunenfeld B
Biochim Biophys Acta; 1987 Oct; 931(1):78-86. PubMed ID: 3651513
[TBL] [Abstract][Full Text] [Related]
7. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.
DeMarzo AM; Oñate SA; Nordeen SK; Edwards DP
Biochemistry; 1992 Nov; 31(43):10491-501. PubMed ID: 1420166
[TBL] [Abstract][Full Text] [Related]
8. RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins.
Terakawa N; Shimizu I; Tanizawa O; Matsumoto K
J Steroid Biochem; 1988 Aug; 31(2):161-6. PubMed ID: 2457133
[TBL] [Abstract][Full Text] [Related]
9. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.
Gill PG; Vignon F; Bardon S; Derocq D; Rochefort H
Breast Cancer Res Treat; 1987 Oct; 10(1):37-45. PubMed ID: 3689980
[TBL] [Abstract][Full Text] [Related]
10. Mammalian progesterone receptor shows differential sensitivity to sulfhydryl group modifying agents when bound to agonist and antagonist ligands.
Moudgil VK; Anter MJ; Hurd C
J Biol Chem; 1989 Feb; 264(4):2203-11. PubMed ID: 2914901
[TBL] [Abstract][Full Text] [Related]
11. Evidence for separate binding sites for progesterone and RU486 in the chick oviduct.
Moudgil VK; Lombardo G; Hurd C; Eliezer N; Agarwal MK
Biochim Biophys Acta; 1986 Nov; 889(2):192-9. PubMed ID: 3778947
[TBL] [Abstract][Full Text] [Related]
12. Effects of antiestrogen versus antiprogestin on transformed and nontransformed steroid receptors.
Turner JW; Ruh MF; Ward DT; Ruh TS
J Steroid Biochem Mol Biol; 1991 Feb; 38(2):197-203. PubMed ID: 2004041
[TBL] [Abstract][Full Text] [Related]
13. Transformation of calf uterine progesterone receptor: analysis of the process when receptor is bound to progesterone and RU38486.
Moudgil VK; Hurd C
Biochemistry; 1987 Aug; 26(16):4993-5001. PubMed ID: 3663641
[TBL] [Abstract][Full Text] [Related]
14. Novel antiprogestins Org 31806 and 31710: interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes.
Mizutani T; Bhakta A; Kloosterboer HJ; Moudgil VK
J Steroid Biochem Mol Biol; 1992 Aug; 42(7):695-704. PubMed ID: 1504008
[TBL] [Abstract][Full Text] [Related]
15. Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element.
Bagchi MK; Elliston JF; Tsai SY; Edwards DP; Tsai MJ; O'Malley BW
Mol Endocrinol; 1988 Dec; 2(12):1221-9. PubMed ID: 3216861
[TBL] [Abstract][Full Text] [Related]
16. An empirical basis for the competition by dexamethasone to progesterone receptors as estimated with the synthetic progestin R5020.
Haslam SZ; McBlain WA; Shyamala G
J Recept Res; 1981-1982; 2(5-6):435-51. PubMed ID: 6891402
[TBL] [Abstract][Full Text] [Related]
17. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors.
Beck CA; Estes PA; Bona BJ; Muro-Cacho CA; Nordeen SK; Edwards DP
Endocrinology; 1993 Aug; 133(2):728-40. PubMed ID: 8344212
[TBL] [Abstract][Full Text] [Related]
18. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines.
Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D
Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427
[TBL] [Abstract][Full Text] [Related]
19. Characterization of estrogen-induced progestin binding in cytosol of the R3327 prostatic carcinoma of the rat.
Mobbs BG; Johnson IE
J Steroid Biochem; 1985 Jan; 22(1):57-62. PubMed ID: 3871881
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a progestin-binding component in lactating rat mammary glands.
Hirose M; Maki M; Chiba H
Biochim Biophys Acta; 1980 Apr; 629(1):168-77. PubMed ID: 7189415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
